ClinicalTrials.gg
Drug

Nintedanib clinical trials

Also written BIBF 1120, Vargatef, Ofev® and Intedanib.

studies test it
141
open now
10
in phase 3
24
first study started
2002

How each study uses nintedanib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the nintedanib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
15 Oct 2014 · OFEV · NDA 205832 (FDA, Drugs@FDA)
European Union
21 Nov 2014 · Vargatef · EMEA/H/C/002569 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Nintedanib
82
Multitargeted Tyrosine Kinase Inhibitor BIBF 1120
8
tyrosine kinase inhibitor BIBF 1120
8
Nintedanib 150 MG [Ofev]
4
OVEF
2

Brand

Vargatef
17
Ofev®
13

Development codes

BIBF 1120
53

Other names

Intedanib
7

Studies by the year they started

140 studies that test it; most in 2015 (14); 1 more planned to start later

Studies that test nintedanib, by start year
YearStudies
20021
20032
20041
20057
20065
20072
20082
20098
20102
20119
20126
20137
201412
201514
201612
20177
20184
20195
20207
202110
20222
20235
20245
20253
20262

Who runs them

Industry 74 · Other 67

Boehringer Ingelheim (61) · Roswell Park Cancer Institute (4) · European Organisation for Research and Treatment of Cancer - EORTC (4) · Assistance Publique - Hôpitaux de Paris (3) · Sunshine Lake Pharma Co., Ltd. (2) · Hospices Civils de Lyon (2) · Memorial Sloan Kettering Cancer Center (2) · M.D. Anderson Cancer Center (2)

Often tested with

Tested in the same studies.

Pirfenidone (11) · Afatinib (5) · Docetaxel (4) · Yinfenidone (2) · Tocilizumab (2) · Nivolumab (1) · Azacitidine (1) · Nerandomilast (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test nintedanib.

Studies

Open first, then newest update. How each study uses nintedanib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 141

See all 141 studies that test nintedanib →

Given beside what is tested · 7 — nintedanib is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with nintedanib

Codes

What other systems call nintedanib · ClinicalTrials.gg INT005300

  • MeSH (NLM) C530716nintedanibConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) G6HRD2P839NINTEDANIBConfirmed FDA, NLM, Wikidata
  • RxNorm 1592737Confirmed FDA, Wikidata
  • Wikidata Q15149723nintedanibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C62765NintedanibOne source FDA
  • DrugBank DB09079One source Wikidata

Also registered as nintedanib esylate (UNII 42F62RTZ4G · RxNorm 1592736).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.